Apogee Therapeutics: Takeaways from our Executive Insights call with Apogee Therapeutics

Research evidence excerpt

Apogee Therapeutics: Takeaways from our Executive Insights call with Apogee Therapeutics

Accessible version

Apogee Therapeutics

Takeaways from our Executive Insights call

with Apogee Therapeutics

Maintain Rating: BUY | PO: 131.00 USD | Price: 82.72 USD

APGE is confident in zumi’s best-in-class profile 11 June 2026

As part of our Executive Insights call series, we hosted APGE’s CEO Michael Henderson, Equity

CCO Jeff Hartness, and CMO Carl Dambkowski to discuss recent updates and the long-

Tazeen Ahmad

term outlook for their lead program, zumilokibart. Management emphasized that 2026 Research Analyst

has been a transformational year, with clinical data in AD supporting differentiated BofAS tazeen.ahmad@bofa.com

Q3M/Q6M maintenance dosing and the recent Blackstone financing deal providing

Daniel Giraldo

funding through commercialization and potentially to profitability. APGE believes zumi’s Research Analyst

Q3M/Q6M profile strongly positions it to be highly competitive and ultimately become a BofAS daniel.giraldoperez@bofa.com

preferred first-line biologic for moderate-to-severe AD, in-line with our physician checks,

Jeremiah Lorentz

while also expanding the biologics market and driving a significant commercial Research Analyst

opportunity. They are on track to initiate the phase 3 program in AD in 2H and expand BofASjeremiah.lorentz@bofa.com

into additional indications including asthma and EoE. We maintain our Buy with $131 Wesley Yon

PO. Research Analyst

BofAS

Zumi’s AD data support differentiated dosing and efficacy wesley.yon@bofa.com Amy Qian

Management highlighted that the 52-week Part A update provided clinical validation for Research Analyst

Q3M and Q6M maintenance dosing, which they view as the key point of differentiation BofASamy.qian3@bofa.com